← All peptidesBlends
Tirzepatide + Cagrilintide
Tirzepatide + Cagrilintide
Dual GLP-1/GIP agonist plus amylin analog, researched as a three-receptor-pathway weight-management stack.
Typical dose
2.5–15 mg
Frequency
Once weekly (titrated)
Half-life
—
Route
subcutaneous
Typical vial sizes
10 mg20 mg40 mg
Sample reconstitution
10 mg vial · 2 mL bac water · 8.75 mg dose
- Draw volume
- 1.750 mL
- Insulin units
- 175 units
- Concentration
- 5.00 mg/mL
- Doses per vial
- 1.1
Research notes
As sold: Tirzepatide 5mg + Cagrilintide 5mg (1:1). Once-weekly; both components titrated up gradually for GI tolerability.
Further reading
- Published research on Tirzepatide + Cagrilintide (PubMed) →
- Clinical trials for Tirzepatide + Cagrilintide (ClinicalTrials.gov) →
Links open live searches on authoritative databases — verify dosing and safety against primary sources.
Research use only.
Information on this page is a reference log compiled from public sources and is not medical advice. Consult a licensed physician before making any decisions about your health.